domenica, 3 maggio 2026

Notizie Newsletter

11 Ottobre 2019

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

Data are limited regarding the use of poly(adenosine diphosphate -ribose) polymerase inhibitors, such as veliparib, in combination with chemotherapy followed by maintenance as initial treatment in patients with high-grade serous ovarian carcinoma. In an international, phase ...
Leggi tutto

11 Ottobre 2019

Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

The efficacy and safety of cabazitaxel, as compared with an androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and had progression within 12 months ...
Leggi tutto

11 Ottobre 2019

7 ottobre 2019 – Attivazione web e pubblicazione schede di monitoraggio – Registro Apixaban (FANV) (Bristol-Myers Squibb/Pfizer)

11 Ottobre 2019

9 ottobre 2019 – Informazioni sulla Brexit

11 Ottobre 2019

9 ottobre 2019 – Simposio GCP 2019 – “Dalla ricerca della Qualità alla Qualità della Ricerca”

11 Ottobre 2019

10 ottobre 2019 – Modifica Registro Pertuzumab (Roche) – Utilizzo dei biosimilari di trastuzumab in associazione a pertuzumab nel carcinoma mammario Her2 positivo metastatico

11 Ottobre 2019

10 ottobre 2019 – Comunicazione EMA sull’uso di creme ad alto dosaggio di estradiolo

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Niraparib, an inhibitor of poly(adenosine diphosphate -ribose) polymerase (PARP), has been associated with significantly increased progression-free survival among patients with recurrent ovarian cancer after platinum-based chemotherapy, regardless of the presence or absence ...
Leggi tutto

Four-week limit for use of high-strength estradiol creams

Oct 4, 2019 - EMA’s safety committee (PRAC) has recommended limiting the use of high-strength creams containing 100 micrograms/gram (0.01%) of estradiol to a single treatment period of up to 4 weeks. This measure is intended to minimise the risk of side effects caused ...
Leggi tutto

EMA Management Board: highlights of October 2019 meeting

Oct 4, 2019 - At its 3 October 2019 meeting in Amsterdam, the European Medicines Agency's Management Board elected Lorraine Nolan as vice-chair of the Board for a three-year period. Dr Nolan is Chief Executive of the Health Products Regulatory Agency (HPRA) in Ireland, a ...
Leggi tutto